Fig. 1

Schematic illustration of experimental procedure and comparison of body weight, cardiac muscle weight, lung weight and liver weight. a Male 12-week-old C57BL/6 mice were divided into four groups: a normal control group (Control), a PG-LPS-treated group (L), a vidarabine-treated group (V), and a PG-LPS plus vidarabine-treated (L + V) group. Chronic infusion of vidarabine was performed for 1-week at a dose of 15 mg/kg/day with the osmotic mini-pumps and the indicated measurements were made. b The Control, PG-LPS, vidarabine and PG-LPS plus vidarabine groups showed similar body weight. NS, not significantly different from the Control (P > 0.05). One-way ANOVA followed by Tukey’s post hoc test). c No significant difference in heart (c), lung (d) or liver size in terms of weight per tibial length (TL) ratio (mg/mm) at 1 week after PG-LPS infusion among the four groups. P = NS, not significantly different from the Control. One-way ANOVA followed by the Tukey’s post hoc test). Data are presented as mean ± SD and scattered dots show individual data